Rocket Pharmaceuticals
RCKT
194 hedge funds and large institutions have $2.67B invested in Rocket Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 67 increasing their positions, 66 reducing their positions, and 17 closing their positions.
162% more call options, than puts
Call options by funds: $33.1M | Put options by funds: $12.7M
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
46% more capital invested
Capital invested by funds: $1.83B → $2.67B (+$836M)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
11% more funds holding
Funds holding: 175 → 194 (+19)
2% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 66
12.3% less ownership
Funds ownership: 111.02% → 98.72% (-12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management
Carouge,
Switzerland
|
+$29.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.6M |
| 3 |
BlackRock
New York
|
+$18M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$10.2M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$8.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$35.2M |
| 2 |
Millennium Management
New York
|
-$21M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$15.4M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$9.16M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.99M |
RCKT Hedge Fund Activity: Q4 2023 in Review
194 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q4 2023, worth a combined $2.67B — up 46% from $1.83B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new RCKT positions and 17 closed out — a net gain of 20 holders — while 67 added to existing stakes and 66 trimmed.
The largest buyer was Pictet Asset Management, opening a new position worth an estimated $29.7M. The largest seller was Maverick Capital, cutting an estimated $35.2M.
- 194 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q4 2023, up from 175 in Q3 2023.
- Funds reported $2.67B of Rocket Pharmaceuticals stock for Q4 2023, up 46% quarter-over-quarter.
- 37 funds opened new Rocket Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +20 holders.
- The largest Rocket Pharmaceuticals buyer in Q4 2023 was Pictet Asset Management, an estimated $29.7M added.
- The largest Rocket Pharmaceuticals seller in Q4 2023 was Maverick Capital, an estimated $35.2M sold.
Based on aggregated 13F filings for Q4 2023.